US Patent Issued to GlaxoSmithKline Intellectual Property Development on Sept. 29 for "IL-33 binding antibodies" (British Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,290, issued on Sept. 29, was assigned to GlaxoSmithKline Intellectual Property Development Ltd. (Stevenage, Great Britain).

"IL-33 binding antibodies" was invented by Martin Orecchia (Stevenage, Great Britain), Matthew Edwards (Stevenage, Great Britain), Andrew Beaton (Stevenage, Great Britain) and Laura Hook (Stevenage, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to the treatment of interleukin 33 (IL-33) mediated diseases, including lung diseases. In particular, the present disclosure relates to IL-33 binding proteins, including anti-IL-33 antibodies, and their uses in the treatment of IL-33 mediate...